Time New York: Mon 18 Dec 13:40 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Cerus Corporation (CERS) Looks Good: Stock Adds 8.2% in Session

Zacks

Cerus Corporation CERS was a big mover last session, as the company saw its shares rise over 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.5–$2.9 in the past one-month time frame, witnessed a sharp increase yesterday.

The price appreciation took place on the back of the news that the U.S. Food and Drug Administration approved the Rhode Island Blood Center's Biologics License Application (BLA) for the interstate distribution of platelets that have been pathogen-reduced with the Intercept Blood System.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cerus currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Cerus Corporation Price and Consensus


A better-ranked stock in the Medical – Products industry is Essilor International SA ESLOY, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is CERS going up? Or down? Predict to see what others think: Up or Down

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.